IXICO plc IXICO and NYU Langone Health sign agreement
16 Ottobre 2020 - 8:00AM
RNS Non-Regulatory
TIDMIXI
IXICO plc
16 October 2020
This is an RNS Reach announcement and the information contained
is not considered to be material or to have a significant impact on
management's expectations of the Group's performance. RNS Reach is
an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute
non-regulatory news releases into the public domain. Information
required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an
RNS regulatory announcement and not on RNS Reach. "
IXICO plc
("IXICO" or the "Company")
IXICO and NYU Langone Health sign agreement to develop
novel imaging markers in multiple system atrophy
IXICO plc (AIM: IXI), the data analytics company delivering
insights in neuroscience, announces that it has entered into an
agreement with NYU Langone Health to support a trial to determine
if the immunosuppressant drug Sirolimus - approved by the FDA to
prevent organ transplant rejection and for the treatment of a rare
and progressive lung disease called lymphangioleiomiomatosis - is
also able to slow the progression of disease in people with
Multiple System Atrophy (MSA). Working with NYU Langone clinicians
and researchers, the trial will help develop biomarkers for MSA
from magnetic resonance imaging (MRI).
MSA is a condition of the central nervous system that causes
gradual damage to nerve cells in the brain. The project involves
application of IXICO's existing MSA analysis solutions on
retrospectively collected MRI data from patients with MSA, dementia
with Lewy Bodies, Parkinson's disease, and Progressive Supranuclear
Palsy as well as the joint development of a novel solution to
analyse susceptibility weighted imaging (SWI).
Dr Robin Wolz, Senior Vice President for Science and Innovation
at IXICO plc, commented: "This collaboration will help to
accelerate the quest for new treatments for Multiple System Atrophy
by bringing together some of the leading researchers in the field
from both academia and industry with the specific goal of
developing new tools to better understand and characterise this
debilitating disease."
Dr. Horacio Kaufman, the Felicia B. Axelrod Professor of
Dysautonomia Research at NYU Grossman School of Medicine and
Director of the Dystonomia Center at NYU Langone Health, added:
"IXICO will bring its expertise in neuroimaging and AI to support
the development and validation of new biomarkers which in turn will
help to identify the most promising treatments and bring these to
patients sooner."
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales)
Walbrook PR Ltd +44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne IXICO@walbrookpr.com
/
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFFLSIMESSEDS
(END) Dow Jones Newswires
October 16, 2020 02:00 ET (06:00 GMT)
Grafico Azioni Ixico (LSE:IXI)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Ixico (LSE:IXI)
Storico
Da Apr 2023 a Apr 2024
